Procaps Group SA banner

Procaps Group SA
NASDAQ:PROC

Watchlist Manager
Procaps Group SA Logo
Procaps Group SA
NASDAQ:PROC
Watchlist
Price: 1.1 USD Market Closed
Market Cap: $124.1m

Multiples-Based Value

There is not enough data to reliably calculate the multiples-based value of PROC.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PROC Multiples-Based Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

PROC Competitors Multiples
Procaps Group SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
LU
Procaps Group SA
NASDAQ:PROC
124.1m USD 0.3 2.4 6.2 9.4
US
Eli Lilly and Co
NYSE:LLY
837.7B USD 12.9 40.6 27.4 29.3
US
Johnson & Johnson
NYSE:JNJ
583.9B USD 6.2 21.8 15.1 18.6
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.3 11.5 12.9
UK
AstraZeneca PLC
LSE:AZN
228B GBP 5.2 29.9 16.5 23.3
US
Merck & Co Inc
NYSE:MRK
292.3B USD 4.5 16 9.9 12.1
CH
Novartis AG
SIX:NOVN
228.6B CHF 5.3 21.2 13.1 16.9
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.3 10 7.5 8.7
US
Pfizer Inc
NYSE:PFE
157.9B USD 2.5 20.3 7.8 10.4
US
Bristol-Myers Squibb Co
NYSE:BMY
120.2B USD 2.5 17.1 7.2 8.9
P/E Multiple
Earnings Growth PEG
LU
Procaps Group SA
NASDAQ:PROC
Average P/E: 19.9
2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.6
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.9
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16
14%
1.1
CH
Novartis AG
SIX:NOVN
21.2
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10
1%
10
US
Pfizer Inc
NYSE:PFE
20.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.1
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
LU
Procaps Group SA
NASDAQ:PROC
Average EV/EBITDA: 45.2
6.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.4
22%
1.2
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.5
13%
1.3
US
Merck & Co Inc
NYSE:MRK
9.9
3%
3.3
CH
Novartis AG
SIX:NOVN
13.1
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.5
1%
7.5
US
Pfizer Inc
NYSE:PFE
7.8
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
LU
Procaps Group SA
NASDAQ:PROC
Average EV/EBIT: 99.2
9.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.3
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
18.6
6%
3.1
CH
Roche Holding AG
SIX:ROG
12.9
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
23.3
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
CH
Novartis AG
SIX:NOVN
16.9
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.7
2%
4.4
US
Pfizer Inc
NYSE:PFE
10.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.9
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett